Testing a new immunotherapy approach before stem cell transplant for Hodgkin lymphoma

Plain-English translation of NCT06377540 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether , an immunotherapy medication that helps your immune system fight cancer, works better when given alongside a stem cell transplant procedure for people with Hodgkin lymphoma that has returned or stopped responding to previous treatments. The study will give the medication before, during, and after the transplant to see if this combination improves outcomes and is safe to use.

Hodgkin lymphoma that comes back after initial treatment or doesn't respond to standard therapies is hard to treat, and doctors want to find better ways to help these patients. This trial explores whether combining this immunotherapy with transplant can improve survival and control of the disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with classic Hodgkin lymphoma that has returned or stopped responding to previous treatment
you are eligible to receive an autologous stem cell transplant (a transplant using your own stem cells) with a BEAM conditioning regimen
you have adequate organ function and healthy enough blood counts to tolerate this treatment
you are in good enough physical condition to handle intensive cancer treatment (ECOG score of 1 or better, or Karnofsky score above 70)
if you have HIV, hepatitis B, or hepatitis C, your infection must be well-controlled or undetectable before starting

You likely don't qualify if…

you have had a severe allergic or immune reaction (grade 2 or higher) to similar immunotherapy drugs in the past
you have received recent chemotherapy (within 3 weeks) or radiation therapy (within 2 weeks)
you have received a live vaccine within the past month
you have an active autoimmune disease or a history of severe autoimmune problems requiring ongoing immunosuppressive medications
you are pregnant, breastfeeding, or planning to become pregnant during the study

What participation looks like

You will receive the medication starting four weeks before your stem cell transplant and continue for one year after the transplant is complete. The medication is given as an injection every three weeks throughout this entire period. You will also undergo the standard stem cell transplant procedure with conditioning chemotherapy, which involves collecting your stem cells, receiving high-dose chemotherapy, and then having your stem cells returned to your body. During the year of treatment, you'll have regular clinic visits for blood work, imaging scans, and monitoring of your health and any side effects.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

United States

Masonic Cancer Center, Minneapolis, Minnesota